Kenvue Inc. (NYSE:KVUE) Shares Acquired by Marathon Capital Management

Marathon Capital Management boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 0.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 149,699 shares of the company’s stock after purchasing an additional 514 shares during the quarter. Marathon Capital Management’s holdings in Kenvue were worth $2,722,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Manchester Capital Management LLC boosted its position in Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after acquiring an additional 530 shares during the period. Mather Group LLC. bought a new stake in shares of Kenvue in the 1st quarter worth $28,000. Riverview Trust Co bought a new stake in shares of Kenvue in the 1st quarter worth $33,000. MV Capital Management Inc. raised its stake in shares of Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after buying an additional 642 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new stake in shares of Kenvue in the 1st quarter worth $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE opened at $23.12 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.55. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The company has a market cap of $44.27 billion, a PE ratio of 29.64, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The stock has a 50-day moving average of $21.21 and a 200-day moving average of $20.03.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter in the previous year, the firm earned $0.32 EPS. The firm’s revenue was down .3% compared to the same quarter last year. As a group, equities research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were issued a $0.205 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue’s dividend payout ratio is 105.13%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of recent analyst reports. Piper Sandler boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft boosted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. UBS Group lifted their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on Kenvue in a report on Tuesday. They set a “buy” rating and a $27.00 price target on the stock. Finally, Citigroup lowered their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $22.10.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.